Navigation Links
Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
Date:2/15/2008

hese cancers in addition to prostate cancer."

In the combination Phase 1 dose-escalating study, 33 patients were treated with one of four doses (60, 80, 100 or 120 mg/m squared) of picoplatin, as well as either 60 mg/m squared or 75 mg/m squared (full-dose) docetaxel plus 5 mg prednisone twice daily. Nine patients received 120 mg/m squared picoplatin and 75 mg/m squared docetaxel every 21 days plus 5 mg prednisone twice daily. This dose, which is also the dose currently under study in the Phase 2 trial, was well tolerated.

Hematological toxicity, including neutropenia, anemia and thrombocytopenia, was dose-dependent and reversible. Neutropenia was the dose-limiting toxicity (DLT). Mild neuropathy (grade 1) was observed in 3 of 33 patients (9 percent) and was unrelated to cumulative picoplatin dose. Neuropathy was infrequent, and no neuropathy of grade 2 or greater was observed. PSA response rate was 65 percent (20 of 31 evaluable patients). Survival data are not yet available. Patient withdrawal from study treatment occurred from death in four patients, progressive disease in eight patients, and withdrawal of consent in one patient. Patients in the Phase 1 trial received a median number of 7 cycles, and 13 of 33 patients completed the maximum of 10 cycles of treatment according to the study protocol.

Based on safety and efficacy data from the Phase 1 study, the recommended Phase 2 regimen of intravenous picoplatin (120 mg/m squared) and docetaxel (75 mg/m squared) every 21 days with prednisone (5 mg) orally twice daily is being evaluated in a Phase 2 study in chemotherapy naive mHRPC patients. PSA response is the primary endpoint; secondary endpoints include radiological response using RECIST criteria, time to progression and survival (1-year, progression-free and overall). The Phase 2 trial completed enrollment in December 2007. The Company expects to present the results of this study in scientific forums later this year.

About Picoplati
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
2. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
5. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
6. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... Forecast – Worldwide Analysis ... Market Analysis Insulin ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
(Date:4/17/2014)... its status as the leading weapon against the deadly ... with new research indicating it simply needs to be ... of the cheap anti-malarial drug chloroquine in treating and ... more than half a million people each year around ... developed resistance to chloroquine, but research carried out at ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
(Date:4/16/2014)... April 16, 2014 According to a new study, ... patients with one to two small polyps are consistent ... This may be an appropriate target for quality indicators. ... quantify adherence to guidelines for timing of repeat colonoscopy ...
(Date:4/15/2014)... frozen fish caused nearly half of all injuries aboard ... on freezer-longliner vessels operating off the coast of Alaska, ... of those injuries and others aboard the two types ... and the research methods used in the study could ...
(Date:4/15/2014)... the University of California, San Diego School of Medicine have ... C virus get liver disease and why the virus is ... , The hard-to-kill pathogen, which infects an estimated 200 million ... mitochondria dismantling the cell,s innate ability to fight infection. ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Changes in processing, handling could reduce commercial fishing injuries 2Health News:Breaking bad mitochondria 2
... Favorite, and ,Have Fun Helping It ... ... Recession? Killer bees? No! Only positive predictions, please.,That,s the attitude of Richard ... debut last month., *(PHOTO 72dpi: Send2Press.com/mediaboom/07-1115-DSamson_72dpi.jpg), *(Photo Caption: SuperLife founder ...
... /Xinhua-PRNewswire-FirstCall/ -- China Sky One,Medical, Inc. (OTC Bullion ... medicinal and diagnostic products in China,today announced that ... Company,s Form 10QSB for the fiscal quarters ended ... filed its full year 2006 amendments on,November 8, ...
... 18 Escalon Medical Corp.,(Nasdaq Capital Market: ESMC) ... clearance from the U.S. Food and Drug,Administration (FDA) ... differential Hematology Analyzer. Drew Scientific plans to,commence shipments ... month-end., "The FDA clearance represents a major ...
... PHILADELPHIA A new brain imaging study by researchers ... Pennsylvania shows that cigarette cravings in smokers who are ... specific regions of the brain. Using a novel method ... MD, associate professor of Neurology at Penn, this study ...
... (NYSE: CDI ),announced today that the Life ... been awarded a contract from CJ CheilJedang,Corporation to ... manufacturing complex to be located in Osong, Korea. ... center for global,distribution of oral solid and sterile ...
... where he worked as a ... ... Dikembe,Mutombo, who is known as much for his philanthropy as his storied ... organization prepare its entry into his home country, the,Democratic Republic of Congo ...
Cached Medicine News:Health News:Six Positive Predictions for 2008, from SuperLife World Service 2Health News:China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 2Health News:Escalon(R) Announces FDA 510(K) Clearance for D3 Hematology System 3Health News:New neuroimaging study identifies 'brain signature' for cigarette cravings 2Health News:CDI-Life Sciences Selected by CJ CheilJedang Corp. to Provide Engineering Design for Major Pharmaceutical Complex in Korea 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 2Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 3Health News:NBA Legend Dikembe Mutombo Joins Opportunity International Board of Advisors; Opens Doors in Democratic Republic of Congo 4